NQO1 and pancreatic neoplasm: The combination of PARPi and β-lapachone, an NAD(P)H:quinone oxidoreductase 1 (NQO1) bioactivatable drug, has synergistic anti-tumor activity and blocks PARP-dependent DNA repair in NQO1-overexpressing cancers such as non-small cell lung cancer, breast cancer, and pancreatic cancer, causing tumor-selective apoptosis [185].